Koerner Michael M, Harper Michael D, Gordon Christopher K, Horstmanshof Douglas, Long James W, Sasevich Michael J, Neel James D, El Banayosy Aly
Advanced Cardiac Care and Transplant Institute, Integris Baptist Medical Center, Oklahoma City, OK, USA.
Ann Cardiothorac Surg. 2019 Jan;8(1):66-75. doi: 10.21037/acs.2018.12.09.
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been shown to be a viable and effective treatment for patients suffering from refractory cardiogenic shock (rCS), which is associated with high mortality rates. Although ECMO therapy used as short-term mechanical circulatory support (MCS) has shown tremendous growth in its application over the past decade, the complication and mortality rates remain high. This retrospective study analyzes complications associated with VA-ECMO support, evaluates the use of defined protocols at a single center, and examines factors that may contribute to patient complication and mortality.
This retrospective analysis included 184 patients who were supported with ECMO from September 2014 through March 2018 at Integris Baptist Medical Center (IBMC). Descriptive statistics were generated to analyze baseline characteristics, demographics, complications, and outcomes.
Acute myocardial infarct (AMI) was the primary etiology of this cohort (N=40; 22%). The mean age was 55±15 (median 56, range 15-84) years. All patients were inotrope and/or vasopressor dependent prior to ECMO initiation. Mean time on ECMO support was 7.8±7.9 days with median time of 6 days. Total patient days on support were 1,430. Most ECMO cannulations, 97 (52%) were performed within Integris Baptist Medical Center, with 48% done outside the hospital; 38% were performed outside of the hospital by the IBMC ECMO team, and 10.5% were performed by an outside team. Bleeding was noted to be the most common VA ECMO complication [N=41; 22.3%; 0.028 events per patient day (EPPD)].
A dedicated 24/7 ECMO service using a multidisciplinary team (MDT) and defined protocols in a single center is able to effectively reduce complications due to VA-ECMO support in the sickest of the sick VA-ECMO patients.
静脉-动脉体外膜肺氧合(VA-ECMO)已被证明是治疗难治性心源性休克(rCS)患者的一种可行且有效的方法,难治性心源性休克死亡率很高。尽管作为短期机械循环支持(MCS)的ECMO治疗在过去十年中的应用有了巨大增长,但其并发症和死亡率仍然很高。这项回顾性研究分析了与VA-ECMO支持相关的并发症,评估了单一中心特定方案的使用情况,并研究了可能导致患者并发症和死亡的因素。
这项回顾性分析纳入了2014年9月至2018年3月在英特里斯浸信会医疗中心(IBMC)接受ECMO支持的184例患者。生成描述性统计数据以分析基线特征、人口统计学、并发症和结局。
急性心肌梗死(AMI)是该队列的主要病因(N = 40;22%)。平均年龄为55±15(中位数56,范围15 - 84)岁。所有患者在开始ECMO治疗前均依赖血管活性药物和/或血管加压药。ECMO支持的平均时间为7.8±7.9天,中位数为6天。患者接受支持的总天数为1430天。大多数ECMO插管(97例,52%)在英特里斯浸信会医疗中心内进行,48%在医院外进行;38%由IBMC的ECMO团队在医院外进行,10.5%由外部团队进行。出血是最常见的VA-ECMO并发症 [N = 41;22.3%;0.028事件/患者日(EPPD)]。
在单一中心使用多学科团队(MDT)和特定方案的全天候专用ECMO服务能够有效降低病情最严重的VA-ECMO患者因VA-ECMO支持导致的并发症。